Archived explainer. For the current picture see today's CMPS page.
COMPASS PATHWAYS ADR ADR (CMPS) is drawing unusual attention today. Our newswire has captured 4 stories on CMPS across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Compass Pathways ADR (CMPS) is moving higher in early trade, with the stock trading around $12.55, up from its opening price of $12.44. The rise comes amid the release of a post-hoc analysis of the COMP360 synthetic psilocybin treatment in a Phase 2 PTSD trial. The analysis showed that the trial's monitoring and support were largely non-directive, with 78% of sessions conducted in silence. This distinction from traditional psychotherapy is being viewed as a key differentiator for the company's approach.
The stock is responding to the publication of a study in the *Journal of Psychopharmacology*, which highlights the minimal and non-directive nature of the COMP360 support provided in the PTSD trial. The findings reinforce the idea that positive outcomes in the trial are primarily linked to the psilocybin treatment itself rather than the therapeutic interaction. This development has drawn attention from traders, with both ATAI and CMPS stocks trending on Stocktwits in pre-market trade. Additionally, HC Wainwright & Co. reiterated its Buy rating on Compass Pathways, maintaining a $70 price target.
Intraday trading has shown a volatile session, with the stock reaching a high of $13.04 and a low of $12.02. The current price of $12.55 represents a move within a broader 52-week range of $3.50 to $15.40. Trading volume has reached 6.6 million shares, which is 1.6 times the 3-month average. The stock has a market cap of $1.8 billion, with a trailing twelve-month earnings per share of -3.08, indicating continued unprofitability. Its beta of 2.49 suggests it is more volatile than the broader market.
The stock is currently without an upcoming earnings date. Investors may want to monitor the breadth of coverage and any further analyst commentary in the coming days as the market digests the latest developments in Compass Pathways' clinical trials.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) is one of the best psychedelic stocks on our list. TheFly reported on July 7 that Oppenheimer reaffirmed its Outperform rating and $20 price target on CMPS shares following new Phase 3 COMP006 26-week results. The firm […]
Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.
A new analysis shows COMP360 monitoring and support in Compass Pathways’ PTSD trial was largely non-directive, with 78% of sessions conducted in silence, highlighting that positive outcomes are linked primarily to the psilocybin experience—not guided psychotherapy.
A Journal of Psychopharmacology analysis found COMP360 PTSD support was minimal and non-directive, distinct from psychotherapy.
More on CMPS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CMPS move explainers: 2026-07-20 · 2026-07-17 · 2026-07-16